| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4239698666735a264ecc71f3577d98e8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1754
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-643
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1841
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate |
2015-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c6101de1b48baf6622b2a019ec83d6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1572d0e8d4405f4b4c65d5fd7e1d867e |
| publicationDate |
2016-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016054107-A1 |
| titleOfInvention |
Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers |
| abstract |
Provided herein are new compositions and methods to target pharmaceutical agents to pathological areas by utilizing bifunctional fusion polymers or nanoparticles. These fusion polymers and nanoparticles contain two or more domains: (i) sequences that bind to exposed collagenous (XC-) proteins present in pathological areas, including cancerous lesions and (ii) domains that bind to pharmaceutical agents. The drug-binding functionality of these fusion polymers and nanoparticles is based on high-affinity, non-covalent interactions. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11299740-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11574747-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3574098-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022082906-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10981980-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020517658-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10913779-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017218355-A1 |
| priorityDate |
2014-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |